These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35772775)

  • 1. IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands.
    Maione L; Albrici C; Grunenwald S; Mouly C; Cimino V; Lecoq AL; Souberbielle JC; Caron P; Chanson P
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3644-e3653. PubMed ID: 35772775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
    Losa M; Garbin E; Pedone E; Mortini P
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
    Gadelha MR; Gordon MB; Doknic M; Mezősi E; Tóth M; Randeva H; Marmon T; Jochelson T; Luo R; Monahan M; Madan A; Ferrara-Cook C; Struthers RS; Krasner A
    J Clin Endocrinol Metab; 2023 Apr; 108(5):e148-e159. PubMed ID: 36353760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
    Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
    Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
    J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
    Wildemberg LE; da Silva Camacho AH; Miranda RL; Elias PCL; de Castro Musolino NR; Nazato D; Jallad R; Huayllas MKP; Mota JIS; Almeida T; Portes E; Ribeiro-Oliveira A; Vilar L; Boguszewski CL; Winter Tavares AB; Nunes-Nogueira VS; Mazzuco TL; Rech CGSL; Marques NV; Chimelli L; Czepielewski M; Bronstein MD; Abucham J; de Castro M; Kasuki L; Gadelha M
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2047-2056. PubMed ID: 33686418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
    Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil.
    Manosso KZB; Sampaio CL; Kasuki L; Antunes X; Gadelha MR; Boguszewski CL
    Endocrine; 2021 Oct; 74(1):146-154. PubMed ID: 34041695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
    Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
    Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
    Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
    Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
    Ilie MD; Tabarin A; Vasiljevic A; Bonneville JF; Moreau-Grangé L; Schillo F; Delemer B; Barlier A; Figarella-Branger D; Bisot-Locard S; Santos A; Chanson P; Raverot G
    J Clin Endocrinol Metab; 2022 Nov; 107(11):2982-2991. PubMed ID: 36136828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
    Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a two-year treatment with slow release lanreotide in acromegaly.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
    Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment.
    Prencipe N; Bona C; Cuboni D; Parasiliti-Caprino M; Berton AM; Fenoglio LM; Gasco V; Ghigo E; Grottoli S
    Pituitary; 2021 Apr; 24(2):242-251. PubMed ID: 33164134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
    Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
    Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
    Riedel M; Günther T; von zur Mühlen A; Brabant G
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
    Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.
    Nista F; Corica G; Castelletti L; Khorrami K; Campana C; Cocchiara F; Zoppoli G; Prior A; Rossi DC; Zona G; Ferone D; Gatto F
    Front Endocrinol (Lausanne); 2021; 12():677919. PubMed ID: 34025586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain.
    Biagetti B; Iglesias P; Villar-Taibo R; Moure MD; Paja M; Araujo-Castro M; Ares J; Álvarez-Escola C; Vicente A; Álvarez Guivernau È; Novoa-Testa I; Guerrero Perez F; Cámara R; Lecumberri B; García Gómez C; Bernabéu I; Manjón L; Gaztambide S; Cordido F; Webb SM; Menéndez-Torre EL; Díez JJ; Simó R; Puig-Domingo M
    Front Endocrinol (Lausanne); 2022; 13():984877. PubMed ID: 36187107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice.
    Geer EB; Sisco J; Adelman DT; Ludlam WH; Haviv A; Liu S; Mathias SD; Gelbaum D; Shi L
    BMC Endocr Disord; 2020 Jul; 20(1):117. PubMed ID: 32736547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.